VisEn, Merck to Co-Develop Fluorescence Agents for Biomarker Imaging | GenomeWeb
NEW YORK (GenomeWeb News) — VisEn Medical and Merck & Co. plan to develop and apply fluorescence agents to image disease-related biomarkers in vivo, VisEn said today.
Merck aims to integrate the companies’ technologies to develop drug candidates and to “establish new standards for the identification and assessment of disease,” said Richard Hargreaves, Merck’s vice president of imaging.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.